Complementary Actions All Around: Lowering Cardiometabolic Risks While Achieving Glycemic Targets with GLP-1 RAs

In episode 2 of the 3-part educational initiative TRANSFORMING TARGETED THERAPY IN ATOPIC DERMATITIS: APPLYING EMERGING DATA AND EVOLVING BEST PRACTICES TO IMPROVE OUTCOMES, dermatologists and allergists discuss overcoming barriers to the use of oral JAK inhibitors. This activity focuses on the mechanistic rationale for the benefit and risk profiles of oral JAK inhibitors, how to address the black box warnings, and making treatment decisions based on patients’ values and goals.

In this activity, an expert in oncology discusses the role of immune checkpoint inhibitors in the care of patients with recurrent and advanced endometrial cancer.

In episode 1 of the 3-part educational initiative TRANSFORMING TARGETED THERAPY IN ATOPIC DERMATITIS: APPLYING EMERGING DATA AND EVOLVING BEST PRACTICES TO IMPROVE OUTCOMES, dermatologists and allergists discuss what practicing clinicians need to know about newly approved oral JAK inhibitors. This activity focuses on the mechanism of action of novel targeted agents, their key safety and efficacy data, and their role in the treatment paradigm for atopic dermatitis.

In this animated, visually-enhanced activity, an expert in hematology-oncology discusses current standards for diagnosing and treating idiopathic thrombocytopenic purpura—and provides an update on the challenges associated with modern care and the promise of novel therapeutic options for disease management.

In this activity, experts in asthma discuss assessing and managing uncontrolled, moderate to severe asthma for pediatric and adult patients, as well as selecting targeted therapies and improving treatment adherence.

In this activity, an expert in women’s behavioral health shares a downloadable tool kit created for OB/GYNs and other clinicians to facilitate the screening, diagnosis, and treatment of postpartum depression (PPD) and to provide guidance on the use of shared decision-making strategies to optimize patient care.

Tumor lysis syndrome (TLS) is a serious and potentially fatal oncologic emergency that, paradoxically, is partially linked to the use of highly effective anticancer treatment. How can the management team rise to the challenge of TLS? In this activity, Anthony R. Mato, MD, MSCE, and Kristen Battiato, MSN, RN, AGNP-C, will provide an answer. Join them as they explore team-based management of TLS and provide guidance on developing TLS management plans. Throughout this program, the experts will use real-world case scenarios to demonstrate how professionals can work together to identify risk factors for TLS, recognize its laboratory and clinical symptoms, and prevent its occurrence.

Episode for Social Workers: Avoiding Roadblocks in Getting Your B-Cell Lymphoma Patients to CAR T-Cell Therapy

Opening the CAR(T) Door to Get Patient to Therapy, episode 4 of the 4-part educational initiative The Evolving Role of CAR T-cell Therapy for R/R B-cell Lymphomas: Improving Access and Outcomes, is designed for community-based oncology clinicians. This CE activity includes conversations among CAR-T experts and a community clinician; it includes patient video clips and numerous downloadable resources including a directory of CAR-T treatment centers organized by state. This activity focuses on managing logistics associated with CAR-T therapy, including common misperceptions, the numerous services offered by treating centers, and how to overcome roadblocks for your patients.

How much do you really know about GLP-1 RAs in the management of T2DM? Test your knowledge about guideline recommendations, current evidence, and strategies to individualize treatment for patients with T2DM using GLP-1 RAs with realistic case-based scenarios. If you need a little help navigating a clinical scenario, a leading endocrinologist will examine current recommendations and evidence for GLP-1 RAs in the management of T2DM, as well as offer his insights on individualizing treatment plans to help patients reach their goals and reduce cardiovascular risks. Think you have all the answers? If so, you’ll be able to take the post-test and claim credit quickly!